The Journal of Pediatrics
Volume 156, Issue 3 , Pages 478-483.e2 , March 2010

Invasive Pneumococcal Infections among Vaccinated Children in the United States

  • Sarah Y. Park, MD

      Affiliations

    • Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA
    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprint requests: Sarah Y. Park, MD, Hawaii Dept of Health, 1132 Bishop St, Suite 1900, Honolulu, HI 96813.
    • ,
  • Chris A. Van Beneden, MD, MPH

      Affiliations

    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Tamara Pilishvili, MPH

      Affiliations

    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Michael Martin, MD

      Affiliations

    • Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA
    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Richard R. Facklam, PhD

      Affiliations

    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Cynthia G. Whitney, MD, MPH

      Affiliations

    • Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • for the Active Bacterial Core surveillance team

Received 19 November 2008 ,Revised 12 August 2009 ,Accepted 12 October 2009.

References 

  1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2000;49(No. RR-9):1–38
  2. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735
  3. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355–361
  4. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–195
  5. Kaplan SL, Mason EOJ, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443–449
  6. Whitney CG, Farley MM, Hadler J, Harrison KH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746
  7. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17–23
  8. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–1502
  9. Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24:2514–2520
  10. (CDC) Centers for Disease Control and PreventionAdvisory Committee on Immunization Practices (ACIP). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. 2008;57:343–344
  11. Nuorti JP, Martin SW, Smith PJ, Moran JS, Schwartz B. Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. Am J Prev Med. 2008;34:46–53
  12. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–1348
  13. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J. 2000;19:394–397
  14. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25:312–319
  15. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–409

 Support for the CDC's Active Bacterial Core surveillance (ABCs) is provided by the CDC's Emerging Infections Program, which had no role in the study design, collection, analyses, or data interpretation; in the writing of the report; or in the decision to submit the findings for publication. The authors declare no conflicts of interest.

PII: S0022-3476(09)01022-1

doi: 10.1016/j.jpeds.2009.10.008

The Journal of Pediatrics
Volume 156, Issue 3 , Pages 478-483.e2 , March 2010

Article Tools

* Image Usage & Resolution